New Delhi [India], May 18: For many people, success is measured only through numbers — revenue, assets, expansion, influence, or profits.
But for Rohit Sethi, life has always meant something far greater than financial achievements alone.
According to those close to him, Rohit Sethi is a man who believes that the greatest blessing a person can truly possess is good health, peace of mind, and the ability to positively impact the lives of others.
Despite managing multiple ventures, responsibilities, and ambitions, he is known for spending a significant part of his time helping people in need, supporting social causes, motivating individuals, and encouraging people to grow stronger mentally, physically, and professionally.
For him, wealth without health has no meaning.
He believes that in today’s world, many people spend their entire lives chasing money while neglecting the most important aspects of life — health, family, peace, purpose, and humanity.
Those who know him describe him as someone constantly balancing business, fitness, discipline, and social responsibility together. Whether through his entrepreneurial journey, fitness lifestyle, or charitable initiatives, Rohit Sethi continues to advocate the importance of becoming stronger not just financially, but also mentally and emotionally.
At the same time, he remains deeply ambitious.
With multiple dreams, projects, and long-term visions, Rohit Sethi is often described as a man who thinks beyond limitations and beyond conventional definitions of success. His mindset revolves around creating impact, building meaningful ventures, empowering people, and leaving behind something larger than personal gain.
However, one aspect that people around him often highlight is that he rarely takes personal credit for his success.
According to those who have worked closely with him, Rohit Sethi consistently credits his journey to the people who stood beside him — his team members, investors, customers, mentors, well-wishers, and the bankers who believed in a young entrepreneur and supported his vision during crucial stages of growth.
He is said to strongly believe that no business can ever be built by one individual alone. Behind every achievement, according to him, are hundreds of people working silently in the background — employees sacrificing time with their families, customers placing trust, investors taking risks, and institutions believing in long-term potential.
Rather than projecting success as an individual victory, he often describes it as a collective effort built on trust, loyalty, discipline, and relationships.
He believes that true legacy is not built merely through money, but through the number of lives one is able to inspire, support, and uplift along the journey.
And perhaps that is where his philosophy stands apart.
Because in the end, no matter how powerful we become, what numbers we touch, what status we achieve, or where we come from — we all eventually leave this world one day.
Money, fame, and position remain behind.
What truly stays is the impact we created, the people we helped, the values we stood for, and the memories we leave in the hearts of others.
For Rohit Sethi, life is not only about building success — it is about building meaning before time runs out.
New Delhi [India], May 18: India’s kajal category continues to remain one of the strongest and most-consumed segments within the beauty industry, with consumers increasingly looking for products that combine long-lasting performance, comfort, and formulation-focused benefits. As the Indian beauty market evolves rapidly, products that balance everyday wearability with high-impact results are witnessing stronger traction across both online and offline channels.
Amidst this growing category, Forever52’s Amazonic Kajal has recently gained attention following celebrity collaborations with actress Shilpa Shetty and TV sensation Nia Sharma. Most recently, Nia Sharma collaborated with Forever52 for a Mother’s Day campaign featuring the brand’s products, including the Amazonic Kajal. The campaign brought additional focus to the product across digital beauty and entertainment platforms while strengthening the brand’s presence within the everyday makeup category.
The increasing focus around the product also reflects a larger shift happening within celebrity beauty collaborations today. Consumers are becoming more selective about the products they purchase, especially in categories used almost daily, such as kajal. Celebrity endorsements are also being viewed more through the lens of credibility, product relevance, and formulation quality rather than simple promotional visibility.
Amazonic Kajal has been positioned as an everyday performance product designed for modern beauty consumers. The kajal features an intense black payoff along with a waterproof and long-lasting formula that lasts for up to 24 hours. The product is dermatologically and ophthalmologically tested and is also vegan, paraben-free, and led-free, making it suitable for regular daily wear.
Priced at INR 249, the Forever52 Amazonic Kajal is available on Nykaa, Tira, Blinkit, Amazon, the brand’s official website, and Forever52 retail stores/offline outlets across India. The product is also among Forever 52’s top-selling products across 1,600 retailers in India, with one Amazonic Kajal sold every minute globally.
In India, kajal continues to remain more than just a makeup essential. It is one of the most-used beauty products across age groups and forms a part of daily makeup routines for millions of consumers. Whether for minimal everyday looks, office wear, festive makeup, or full glam routines, kajal remains a staple category with consistently high consumer demand. As a result, the market has become increasingly competitive, with buyers expecting products to deliver strong pigmentation, smudge resistance, smooth application, and long-hour comfort simultaneously.
Alongside performance, formulation-focused beauty has also become a growing priority among Indian consumers. Buyers today are paying closer attention to the products they use around the eyes and are increasingly looking for options that feel safer and more suitable for regular wear. This has led to stronger demand for products that combine performance-driven features with dermatologically and ophthalmologically tested formulations.
The growing traction around Amazonic Kajal also highlights the increasing demand for affordable performance makeup within India’s beauty industry. Consumers today are actively seeking products that offer premium-looking results without entering luxury price points. With a combination of long wear, waterproof performance, accessibility, and celebrity associations, the product continues to strengthen its positioning within the affordable everyday makeup segment.
As India’s beauty industry continues to expand rapidly, the kajal category remains one of the most competitive and high-consumption segments in the market. With rising consumer awareness around formulations and increasing demand for everyday performance products, Forever52’s Amazonic Kajal continues to strengthen its presence among modern Indian beauty consumers looking for products that combine performance, accessibility, and everyday wearability.
About Forever52
Established in 2008 in the UAE, Forever52 has expanded its presence across 40+ countries globally and launched in India in 2018. Known for its professional-quality makeup and trend-forward beauty products, the brand has built a strong presence among makeup artists, creators, and beauty consumers. Forever52 continues to focus on creating innovative, high-performance products designed for everyday wearability and modern beauty needs.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
Nagpur (Maharashtra) [India], May 18: Shweta Chopra, founder and CEO of premium handcrafted chocolate brand INDULGENCE, attended the 79th Cannes Film Festival this week as part of a targeted business delegation that combined industry networking with international market outreach.
Chopra — an engineer with an MBA and specialised training in advertising, public relations, and artisan confectionery in the UK — used the Cannes platform to advance INDULGENCE’s export and collaboration strategy. Across curated meetings with creative and luxury-sector executives, she showcased the brand’s made-to-order corporate gifting solutions and signature chocolate collections, emphasizing artisanal craftsmanship and bespoke packaging tailored for high-end clients.
At Cannes, INDULGENCE presented several new seasonal and corporate lines designed for premium events and festivals, positioning the company to service multinational brands and luxury hospitality partners. Chopra highlighted the brand’s capability to scale production while maintaining small-batch quality, and discussed prospective partnerships focused on co-branded gifting and limited-edition runs.
Chopra also made a high-profile appearance on the Cannes red carpet, a moment she framed as a statement of women’s strength and entrepreneurial ambition. Walking the carpet in a tailored, sustainably sourced gown that married contemporary minimalism with South Asian detailing, she balanced glamour with purpose. The look, hairstyled and accessorised to complement INDULGENCE’s refined aesthetic, drew praise on the festival circuit and reinforced the brand’s narrative of heritage craftsmanship meeting modern luxury.
INDULGENCE currently serves corporate clients with customised gifting for events, campaigns, and executive hospitality. Chopra said Cannes offers “an invaluable window into global consumer trends and partner ecosystems,” underscoring the role such forums play in scaling women-led businesses on the international stage. Would you like this edited for a print column or a social post?
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
New Delhi [India], May 18: Fusion Finance announced its Q4FY26 and full-year FY26 results, reflecting a strong recovery in operating performance led by sustained improvement in collection efficiency, asset quality, write-off recoveries, and portfolio performance, which led to a sharp reduction in credit costs during the quarter. The Company closed FY26 on a significantly stronger footing, with improving business momentum and a strengthened balance sheet.
Fusion Finance returned to full-year profitability.
Continued strengthening in portfolio quality and disciplined growth in disbursements.
AUM at Rs 7407 crore as of March 2026, growing 8% over the sequential quarter.
Collection efficiency and recoveries improved significantly, driving lower credit costs and stronger profitability.
Avg. Collection efficiency on portfolio outstanding improved consistently during the year and reached 99.66% in Q4FY26, the highest level over the last several quarters, and the new book, as per tighter guardrails, performed with an avg CE of 99.77% during the quarter. This was achieved by focused recovery efforts, disciplined field execution, and continued customer engagement.
The strengthening in collections translated into a significant improvement in asset quality metrics during the quarter. Gross NPA improved to 3.21% in Q4FY26 from 4.38% in Q3FY26, while Net NPA improved to 0.51% from 0.63% in the previous quarter.
Improved portfolio quality and stable collection trends also resulted in a meaningful reduction in credit costs. Credit cost as per the ECL model for Q4FY26 stood at Rs 56 crore, declining 30% sequentially and 78% year-on-year. Net P&L impact from credit costs reduced to Rs 32 crore during the quarter, compared to Rs 65 crore in Q3FY26 and Rs 247 crore in Q4FY25.
Reflecting the improvement in operating performance, Fusion reported Profit After Tax (PAT) of Rs 114.2crore for Q4FY26, after including the Deferred Tax Asset (DTA) recognition of Rs 76.8 crore during the quarter. Excluding the DTA recognition, profitability improved materially on the back of superior credit costs, improved recoveries, and stable operating performance, with Q4FY26 profit at INR 37.4 Crore. For the full financial year FY26, the company returned to profitability and reported a PAT of Rs 13.9crore.
After multiple quarters of calibrated normalization, Fusion’s Assets Under Management (AUM) grew to Rs 7,407 crore as of March 31, 2026, registering an 8% sequential increase. Quarterly disbursements grew 34% QoQ and 85% YoY to Rs 2,140 crore, reflecting calibrated business momentum alongside continued focus on portfolio quality.
Net Interest Margin (NIM) improved to 11.44% in Q4FY26 from 11.32% in Q3FY26, supported by better portfolio yields, improving asset quality, and lower marginal cost of borrowing.
Commenting on the performance, Mr. Sanjay Garyali, MD & CEO, Fusion Finance Limited, said: “The quarter reflects the steady strengthening of our core operating metrics. Our focused efforts on improving collection efficiency, driving disciplined recoveries, and maintaining prudent underwriting standards have resulted in strong improvement in portfolio quality across the business. The decline in GNPA, NNPA, and credit costs demonstrates the effectiveness of our risk management and execution capabilities. As collection trends stabilize further, we remain focused on pursuing sustainable growth while maintaining portfolio quality and operational discipline.”
Fusion continued to strengthen its pan-India distribution network during the year, with presence across 1,536 branches in 22 states and 3 Union Territories.
Mumbai (Maharashtra) [India], May 18: Cupid Limited (Cupid, The Company) announced its strongest-ever quarterly performance in Q4 FY26 (quarter ended 31st March 2026), driven by strong execution, consistent demand momentum, and improved traction across key business segments.
Building on this strong close to the year, the Company has entered FY27 with healthy business momentum, supported by a strong order book, improving execution visibility, and sustained demand across markets, providing confidence for continued growth ahead.
– Operating Income of ₹ 357.71 Cr, YoY growth of 95%
– EBITDA of ₹ 116.70 Cr, YoY growth of 180%
– PBT of ₹ 142.47 Cr, YoY growth of 160%
– Net Profit of ₹ 108.23 Cr, YoY growth of 165%
Note: Percentage figures have been rounded off to the nearest whole number
Historic Quarterly Performance & Growth Momentum
·Q4 FY26 stands as the strongest quarter in the Company’s history, with Cupid Limited surpassing its FY26 annual guidance of ₹335 Cr revenue and ₹100 Cr net profit, reflecting exceptional business momentum and execution strength
·Strong performance was driven by scale-up across key business segments, supported by improved operating leverage, efficient execution and sustained demand momentum
·Healthy traction continues across domestic and international markets, providing strong visibility for continued growth ahead
·Strongest ever order pipeline continues across global institutional agencies, government procurement programs and FMCG channels
Product Mix & Business Scale-Up
·Male condoms remained the largest revenue contributor with revenue contribution of ~₹181.11 Cr during FY26
·Female condoms contributed ~₹60.72 Cr, supported by increasing global demand and expanding procurement opportunities
·Newly launched FMCG Products contributed ~₹84.26 Cr during FY26 and continues to scale rapidly with expanding retail distribution and consumer reach
·IVD kits and Personal Lubricant contributed ~₹24.97 Cr with gradual scale-up and increasing market opportunities
·Diversified product portfolio across healthcare, wellness, diagnostics and FMCG categories continues to strengthen the overall business mix
Export Business & Global Expansion
·Exports contribute ₹208.13 Cr, accounting for 59.30% of revenue. The Company exports its products to over 125 countries, with a strong presence across Africa and other high-demand international markets
·Sharp focus continues on strengthening exports business and expanding international presence across regulated as well as emerging markets
·Global footprint expansion of approximately 35% is targeted over the coming year through deeper market penetration, strategic partnerships and increasing participation in international procurement programs
·Increasing penetration into regulated markets continues to be supported by certifications, technological capabilities and long-standing global relationships
·Healthy institutional demand and repeat business from leading global procurement agencies continue to support long-term international growth visibility
·USD/INR exchange rates currently remain among the highest levels witnessed historically, expected to act as a favourable tailwind given the Company’s meaningful export exposure and growing international operations
FMCG Expansion & Style Baazar Ecosystem
·Aggressive expansion of FMCG distribution footprint across India continues, supported by increasing consumer penetration and strengthening retail access
·Strategic investment of ₹331.53 Cr in Baazar Style Retail Limited significantly strengthens FMCG distribution ecosystem and market reach
·Initial deployment of ₹82.88 Cr representing 25% of the total investment has already been completed with allotment of 1,01,00,000 warrants
·Access to a rapidly expanding retail network of 250+ stores is expected to improve shelf presence, last-mile reach and product availability across key markets
·Planned expansion of the Style Baazar network to 500+ stores over the next 2–3 years is expected to significantly enhance consumer touchpoints and brand visibility
·Faster rollout of the expanding FMCG portfolio is expected through stronger store-level execution and consumer insights
·The Style Bazaar ecosystem is expected to support approximately ₹150 Cr incremental revenue in FY27 with scale-up potential to approximately ₹500 Cr annual revenue over the medium term
·Integrated go-to-market strategy combining manufacturing scale, brand building and retail distribution capabilities is expected to support long-term FMCG growth
Strategic Investments & Ecosystem Expansion
·Strategic investments in GII Healthcare Fund and Baazar Style Retail Limited are expected to create significant long-term value through both standalone appreciation and broader ecosystem advantages
·Investments remain aligned with the broader vision of strengthening presence across healthcare, wellness, FMCG and retail distribution ecosystems
·These strategic initiatives are expected to create additional avenues for long-term value creation while supporting future business scale-up opportunities
Nitrile Female Condom & Dual Polymer Expansion
·Development Program for nitrile female condoms commenced during the quarter, targeting a premium global segment historically supplied by a single global manufacturer
·Global female condom market was estimated at approximately $770 Mn in 2024 and is projected to exceed approximately $1.2 Bn by 2030, with nitrile positioned as a premium latex-free category
·Growing demand from global procurement agencies for supply diversification continues to create strong opportunities within the segment
·25–35% Higher pricing compared to latex alternatives, along with strong technical, regulatory, and supply chain entry barriers,continue to make the segment strategically attractive
·New manufacturing facility has been designed with integrated dual polymer dipping capability enabling production of both Natural Rubber Latex and Nitrile condoms on dedicated lines without cross-contamination
·Integrated dual polymer capability positions Cupid as the only condom manufacturer in India with manufacturing capabilities across male condoms, female condoms and nitrile female condoms
·Upon full commissioning, expanded manufacturing capacity is expected to support annual production of approximately 1.25 Bn male condoms and approximately 125 Mn female condoms
Branding & Technology Positioning
·“Made in India with Japanese Quality” initiative continues to strengthen the Company’s global positioning and brand differentiation
·Collaboration with Asia’s oldest latex condom manufacturer further strengthens technological and manufacturing capabilities
·Branding strategy remains focused on enhancing positioning across domestic consumers as well as global OEM partners
Diagnostics & Regulatory Certifications
·During FY26, CE (EU IVDR) certification was received for HIV 1&2 Antibody, Hepatitis B,Syphilis and Pregnancy test kits.
·Certification under EU IVDR 2017/746 representsone of the most stringent global regulatory standards for diagnostics products
·Access to European Economic Area markets and other CE recognised geographies is expected to significantly strengthen international opportunities
·Eligibility for government tenders, multilateral healthcare programs and large-scale public health screening initiatives globally has further strengthened following the certification
Raw Material Security & Operating Environment
·Raw material inventory remains comfortably secured for well over six months across key product categories, including inputs linked to crude derivatives
·Strategic inventory positioning is expected to support operational stability, uninterrupted execution and margin resilience across domestic and international markets
·Demand across global B2B and India focused B2C FMCG businesses continues to remain robust and buoyant, supported by expanding distribution, sustained institutional demand and growing consumer penetration
·Strong raw material security and favourable global demand trends continue to position the business well to navigate inflationary cycles while sustaining growth momentum
Strategic Growth Outlook
Building on strongest ever operational momentum, expanding FMCG distribution network, growing international opportunities and ongoing capacity expansion initiatives, Cupid Limited remains strategically positioned for significant scale-up over the next three financial years.
·Rapid expansion of FMCG distribution footprint across India
·Increasing contribution from high-margin B2C business
·Capacity expansion across male and female condom portfolio
·Growth in global institutional and government tenders
·New product additions across lubricants, wellness and diagnostics
·Operating leverage benefits from scale and backward integration efficiencies
·Continued focus on disciplined execution, margin expansion and long-term shareholder value creation for shareholders
Commenting on the performance, Mr. Aditya Kumar Halwasiya, Chairman and Managing Director, said, “We have delivered a historic performance in FY26, surpassing our annual guidance and reporting revenue of ₹ 358 Cr and net profit of ₹108 Cr. This performance reflects strong execution, improving operating leverage, and sustained demand across our businesses, resulting in our strongest-ever quarterly and full-year performance.
During the quarter, we commenced the development Program for nitrile female condoms, entering a premium segment which has historically been supplied by a single global manufacturer. Backed by our dual polymer manufacturing capability, we are uniquely positioned as the only manufacturer in India with the ability to produce both latex and nitrile condoms, with a planned capacity of ~1.25 billion male condoms and ~125 million female condoms annually.
We have also strengthened our global positioning through our ‘Made in India with Japanese Quality’ initiative, supported by our collaboration with one of Asia’s oldest condom manufacturers, reinforcing our focus on quality and technological excellence.
In diagnostics, we further strengthened our regulatory portfolio during FY26 with the receipt of CE EU IVDR certification for our HIV and Hepatitis B test kits, along with CE certification for our Syphilis and Pregnancy test kits. These approvals collectively enhance our access to regulated markets such as Europe while strengthening our participation in global public health programs.
On the domestic front, our strategic investment of ₹331.53 Cr in Baazar Style Retail significantly strengthens our FMCG distribution. We have already deployed ₹82.88 Cr, providing access to a retail network of over 260 stores, which is expected to scale beyond 500 stores over the next 2 to 3 years. This ecosystem is expected to generate ~₹150 Cr incremental revenue in FY27 and scale up to ~₹500 Cr annually over the medium term, while significantly improving our brand visibility and last mile reach.
Looking ahead, with strong export momentum, a favorable currency environment, and a well-secured raw material position, we are confident of sustaining this growth trajectory and achieving our FY27 revenue target of ₹600 Cr with net margins above 30%, as we continue to build a scalable and globally competitive business.”
About Cupid Limited
Established in 1993, CUPID Limited, India’s premier manufacturer and brand of male and female condoms, water based personal lubricants, IVD kits, deodorants, perfumes, almond hair oil, body oils, petroleum jelly and other FMCG Products. The company operates with a strong commitment to public health and well- being, maintaining ethical business practices aligned with international standards. In alignment with its strategic growth plans, the company has recently expanded its product offerings to include Fast-Moving Consumer Goods (FMCG) such as fragrance products (Eau De Parfums, Deodorants, Pocket Perfumes), personal care items (Toilet Sanitizers, Hair & Body Oils, Hair Removal Sprays, Face Wash), and other wellness solutions. In March 2024, the company completed a strategic land acquisition in Palava, Maharashtra, enabling it to amplify its production capacity by 1.5 times the existing output. As a result, the annual production capacity will be augmented by approximately 770 million male condoms and 75 million female condoms. The company has a prominent presence in international markets and is the first company in the world to attain WHO / UNFPA pre-qualification for both male and female condoms. CUPID currently exports its products to over 125 countries, with a substantial portion of its revenue generated from international markets. Furthermore, CUPID has established a long-term agreement with WHO / UNFPA. The company is listed on BSE (BSE: 530843) and NSE (NSE: CUPID).
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
Mumbai (Maharashtra) [India], May 18: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730)is pleased to announce the launch of “HORMONE RANGE PRODUCTS, its premium specialty therapeutics brand focused on longevity, hormone health, recovery science, and human performance solutions. The initiative marks Fredun’s strategic entry into a rapidly expanding, high-value healthcare segment driven by increasing global demand for preventive, performance-oriented, and precision-based therapeutics.
Built on a doctor-led, ethical, and evidence-backed pharmaceutical model, the hormone range products combine clinical credibility with a digital-first patient/doctor engagement ecosystem to deliver an integrated healthcare experience focused on outcomes, adherence, and long-term patient value. The range is designed to address the growing shift from traditional disease management towards healthy lifespan optimization, preventive care, and advanced performance therapeutics.
Strategic Highlights
·Strategic expansion into high-growth longevity and specialty hormone therapeutics
·Doctor-led and evidence-backed platform focused on clinical outcomes
·Premium positioning in hormone health, recovery science, and performance care
·Digital + Pharma hybrid model enabling end-to-end patient engagement
·Focused on precision-driven, high-margin, and differentiated therapeutic categories
·The range of products will work hand in hand with our protein supplement range and help
strengthen our reach within the existing demographic, while enabling us to offer a more comprehensive approach towards preventive healthcare, wellness, and performance therapeutics
The initial portfolio includes therapies and formulations based on testosterone and its salts, nandrolone, growth hormone-oriented solutions, and supportive hormone optimization therapies, developed to meet specialised clinical requirements under appropriate medical supervision. The platform is further supported by protocol-driven patient monitoring, doctor engagement, and direct-to-patient fulfillment capabilities designed to improve treatment continuity and patient adherence.
The brand leverages Fredun Pharmaceuticals Limited’s established strengths in pharmaceutical formulation development, quality-focused manufacturing, and global distribution capabilities, while creating new opportunities in premium, innovation-driven therapeutic segments. ADARO is positioned to build a differentiated presence through scientific quality, regulatory alignment, premium product experience, and clinically guided treatment pathways.
Core Business & Growth Drivers
·Premium, science-driven therapeutic positioning
·Focus on hormone optimization and preventive healthcare
·Digital-led patient acquisition and retention strategy
·Specialised formulations with strong clinical orientation
·Direct-to-patient engagement and subscription-based continuity model
·Expansion into emerging high-growth healthcare categories
With increasing consumer and medical focus on vitality, metabolic health, recovery science, and preventive wellness, Fredun believes its hormone range products are well-positioned to address an evolving market opportunity through a trusted, outcomes-focused, and ethically driven pharmaceutical approach. The launch further reinforces the Company’s long-term vision of building a diversified and future-ready healthcare portfolio spanning both large-scale generics and advanced specialty therapeutics.
Commenting on the development, Mr. Fredun Medhora, Managing Director, Fredun Pharmaceuticals Limited said: “The launch of our hormone range products represents a significant milestone in our journey towards building a more specialised and future-ready pharmaceutical portfolio. As we move up the value chain, our focus is on entering segments that demand high scientific rigor, clinical validation,and manufacturing excellence. This range reflects our vision by bringing together medical expertise andevidence-based formulations to create a credible presence in hormone and performance therapeutics.”
About Fredun Pharmaceuticals Limited
Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company’s objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.
In the FY25, Fredun reported total revenues of ₹ 456 Cr, with an EBITDA of ₹ 55 Cr and a PAT of ₹ 21 Cr.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
Jamshedpur (Jharkhand) [India], May 16: Building on the successful launch of its pioneering executive education initiative in public policy and leadership, XLRI – Xavier School of Management has commenced admissions for the second batch of its flagship Public Policy & Sustainable Leadership (PPSL) programme.
Launched in collaboration with the Department of Personnel & Training (DoPT), Government of India, PPSL, the one-year hybrid executive programme, has emerged as a distinctive interdisciplinary platform bringing together policymakers, administrators, academicians, development professionals, sustainability practitioners, and professionals from the private sector under one academic ecosystem. One of the unique elements of the programme is the eclectic class mix comprising both government-sponsored candidates and self-sponsored candidates.
The inaugural cohort includes officers from the Government of India (IAS, IPS, IFoS, and State Civil Service officers) and various state governments, senior professionals from UN Women, PSI India, Council on Energy, Environment & Water (CEEW), PCI India, IBM Research Labs, and academicians from public administration institutes.
The 180-hour programme has been carefully designed to accommodate working professionals through a hybrid delivery format combining two short immersive campus residencies with interactive online sessions held on Sundays. It offers a multidisciplinary curriculum covering public policy, public finance, public management, public systems, governance, sustainability, leadership, stakeholder engagement, business strategies & non-market strategies, and emerging developmental challenges.
Speaking about the programme’s relevance and impact, Prof. Kalyan Bhaskar, Associate Professor, XLRI and Programme Director of PPSL, stated:
“The PPSL programme reflects XLRI’s larger vision of creating responsible leadership at the intersection of public policy, governance, civil society, and public value creation. The diversity of the participants enriches classroom discussions, peer learning, and enables meaningful dialogue between administration, academia, development sector, and industry.”
With increasing complexities in public policy, governance, sustainability transitions, and public administration, the programme aims to create a new generation of leaders capable of designing inclusive, ethical, and evidence-driven solutions for society.
The second batch is expected to further strengthen the programme’s relevance by fostering collaborative learning among officers, practitioners, and professionals working across public systems and developmental institutions.
The last date for application is 18th August 2026. The program commences on 18th September 2026 with the inaugural campus component at XLRI Jamshedpur.
More details about the programme, eligibility, and admissions are available at the XLRI website.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
New Delhi [India], May 16: Tourism Finance Corporation of India Limited(TFCIL, The Company), (NSE – TFCILTD | BSE – 526650), one of the leading companies providing financial assistance to tourism-related projects have announced its Audited Financial Results for Q4 FY26.
Key Financial Highlights
Key Financial Highlights Q4 FY26
•Total Income of ₹ 73.94 Cr, YoY growth of 6.46%
•EBITDA of ₹ 65.29 Cr, YoY growth of 7.17%
•PAT of ₹ 32.02 Cr, YoY growth of 6.03%
•EPS of ₹ 0.69, YoY growth of 6.15%
Key Financial Highlights FY26
•Total Income of ₹ 276.83 Cr, YoY growth of 6.45%
•EBITDA of ₹ 249.45 Cr, YoY growth of 6.59%
•PAT of ₹ 123.46 Cr, YoY growth of 18.93%
•EPS of ₹ 2.67, YoY growth of 19.20%
FY26 Key Highlights
Financial Position:
·Tangible Net Worth stood at ₹1,304.84 Cr in FY26, reflecting ~8% YoY growth.
·Gross Loans (AUM) increased significantly to ₹2,088.14 Cr in FY26 (23% YoY growth).
Asset Quality:
·Gross NPA improved sharply to 0.37% in FY26 from 3.22% in FY25.
·Net NPA reduced to Nil in FY26 from 1.61% in FY25, reflecting strong recoveries and a clean asset book.
Operational Efficiency:
·Net Interest Margin (NIM) improved to 6.43% in FY26 from 5.07% in FY25.
·Return on Loans & Advances increased to 12.70% in FY26 from 12.45% in FY25.
·Operating expenses remained controlled at ₹27.94 Cr in FY26, reflecting disciplined cost management.
Capital Adequacy & Gearing:
·Capital Adequacy Ratio (CRAR) remained strong at ~55.53% in FY26, well above regulatory requirements.
·Debt-to-Equity (Gearing) stood at 0.83:1 in FY26, indicating a stable and prudent capital structure.
Operational Highlights:
·The Company’s gross portfolio expanded to ₹2,188.87 Cr in FY26, reflecting strong growth momentum.
·Loan portfolio stood at ₹2,088.14 Cr across 63 borrowers in FY26, indicating a diversified credit base.
·The portfolio remains well-diversified, led by Hotels (52%), followed by Real Estate (19%) and Manufacturing (12%), with Infrastructure & Social Infra contributing 5%.
·Exposure to NBFCs (4%) and Loan Against Shares (3%) remains calibrated, ensuring prudent risk management.
·The Company maintains a pan-India presence, with key exposures in Uttar Pradesh, Maharashtra, and Gujarat, supporting geographic diversification.
·TFCI is actively expanding into solar financing for hotels, resorts, and tourism-linked MSMEs, aligning with sustainability trends and enhancing portfolio diversification.
·The Company is well-positioned to benefit from urbanisation and hospitality-led real estate growth, emerging as a key NBFC enabler in mixed-use developments and renewable infrastructure.
·TFCI has undertaken strategic initiatives in the alternative investment space, acting as a co-sponsor and anchor investor in Holystone Hospitality Fund (Category II AIF).
·The Company has also committed as an anchor investor in Certus Real Estate Fund (Category II AIF), strengthening its real estate investment platform presence.
·Further, TFCI has invested in Oxyzo Credit Fund I, a debt-focused Category II AIF, enabling exposure to diversified sectors and enhancing yield opportunities.
About Tourism Finance Corporation of India Limited
Tourism Finance Corporation of India Limited (TFCI), established in 1989, is a premier public financial institution dedicated to providing finance and advisory services to India’s tourism sector. Over the years, TFCI has expanded its portfolio to include financing for educational and healthcare institutions, NBFCs, affordable and mid-income housing projects, logistics and warehousing, manufacturing sectors, solar projects, and Loan Against Securities.
With a proven track record of contributing to the development of over 50,000 star-category hotel rooms and landmark attractions such as Taj Resorts in Kerala & Goa, Umaid Bhawan Palace Heritage Hotel, Ananda in the Himalayas, Palace on Wheels, Essel World, Shanku Water Park, and Imagicaa, TFCI has played a pivotal role in shaping India’s tourism landscape. The company has also provided strategic advisory and feasibility services to the Ministry of Tourism and several State Tourism Departments, enabling large-scale tourism development projects.
In FY26, the company reported a Total Income of ₹276.83 Cr, EBITDA of ₹249.45Cr, Net Profit of ₹123.46 Cr, and EPS of ₹2.67.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
New Delhi [India], May 16: Gujarat-based director producer Chanda Patel once again brought Indian elegance and cinematic pride to the global stage as she walked the red carpet at the prestigious 79th Cannes Film Festival. Representing India with grace and confidence, Chanda attended the premiere of her film Tera Mera Nata, making a powerful statement about the growing presence of Indian independent cinema at internationally celebrated platforms.
Draped in a stunning ivory and pastel couture ensemble featuring intricate embroidery, shimmering embellishments, and a dramatic flowing trail, Chanda Patel turned heads with her sophisticated and regal appearance. Her outfit beautifully blended traditional Indian craftsmanship with contemporary global fashion, perfectly complementing the glamour and grandeur of Cannes. Styled with soft curls, elegant jewellery, and subtle makeup, she carried an effortless charm that caught the attention of photographers, fashion critics, and international attendees alike.
Known for supporting emotionally rooted and culturally rich storytelling, Chanda Patel has steadily carved her own space in the entertainment industry. Her film Tera Mera Nata received appreciation for its emotional depth and heartfelt narrative, with its Cannes premiere becoming a proud moment not only for the team but also for regional Indian cinema. Industry insiders praised Chanda’s vision as a producer and her commitment towards bringing meaningful stories to wider audiences.
Her continued presence at Cannes reflects the rising influence of Indian producers on the world cinema map. Beyond the red carpet glamour, Chanda Patel symbolises the spirit of modern Indian filmmaking — rooted in culture yet global in vision. Her poised appearance, warm personality, and confident representation of Gujarat and India added a distinct charm to the festival this year.
Speaking about the experience, Chanda Patel shared that walking at Cannes and presenting Tera Mera Nata on such a respected international platform is both an honour and an emotional milestone in her journey as a producer.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
From India to the World: Naman Gosalia and AnginaX Are Taking Cardiovascular Prevention to the Global Stage
Geneva [Switzerland], May 16: In a proud moment for India, Naman Gosalia’s consistent advocacy for making cardiovascular prevention the default, not optional, is now bringing India-born AnginaX into global healthcare and public-health conversations alongside presidents of leading cardiology societies, global healthcare leaders, policymakers, institutions, and international public-health stakeholders from across the world.
His growing voice on prevention-first healthcare has led to invitations to discussions at World Heart Federation forums and broader health-policy conversations aligned with the United Nations ecosystem, where the future of cardiovascular prevention is increasingly becoming a global priority.
For decades, healthcare systems around the world have largely focused on treating heart attacks after they happen.
Naman Gosalia believes the future of healthcare will be defined by something far more important: preventing them before they begin. That belief is now taking India-born AnginaX onto the global stage.
At a time when cardiovascular disease claims nearly 18 million lives annually worldwide, according to the World Health Organization, Gosalia has become a leading advocate for moving healthcare earlier, before symptoms, before emergencies, and before patients reach catastrophic stages of disease.
As the Founder of AnginaX, he is leading a prevention-first cardiovascular model that integrates advanced medical science, precise preventive pathways, and intelligent systems into a single, continuous approach to lifelong cardiovascular health.
The objective is ambitious but deeply human: to ensure people do not enter healthcare for the first time only after a crisis begins.
During a recent podcast conversation on GunjanShouts, Gosalia summarized the philosophy behind the movement:
“Our fight is against the disease. We don’t want to save lives only at the ICU; we want to protect lives much earlier, while people are still at home.”
His advocacy is increasingly resonating across clinicians, hospitals, policymakers, and public-health stakeholders exploring how prevention can become a continuous layer integrated into routine healthcare delivery at a real population scale.
Through AnginaX, Gosalia has brought together cardiologists, physicians, scientists, researchers, engineers, and technologists around one mission: shifting healthcare from reactive treatment toward continuous cardiovascular health building.
Rather than positioning prevention as occasional screening, the vision focuses on enabling earlier awareness and action before cardiovascular disease progresses toward angina, heart attack, stroke, or catastrophic events.
Healthcare systems globally continue to face rising chronic disease burden, increasing emergency care costs, and overwhelmed infrastructures. In that environment, prevention is no longer being viewed as a future aspiration.
It is increasingly becoming a necessity.
For many across India, this represents a proud moment, an Indian-born prevention vision beginning to influence how the world approaches cardiovascular health at a population scale.
And while the conversations around AnginaX continue to expand internationally, Gosalia’s central message remains remarkably clear:
“The future of healthcare will not be defined by how well we treat heart attacks; but by how effectively we prevent them.”
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
